497 related articles for article (PubMed ID: 25495503)
1. Comprehensive dietary education in treated gout patients does not further improve serum urate.
Holland R; McGill NW
Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
[TBL] [Abstract][Full Text] [Related]
2. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
3. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
4. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
6. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a urate lowering regimen in primary gout.
Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
[TBL] [Abstract][Full Text] [Related]
9. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI
BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386
[TBL] [Abstract][Full Text] [Related]
11. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
12. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
13. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
15. Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity.
Wood R; Fermer S; Ramachandran S; Baumgartner S; Morlock R
J Rheumatol; 2016 Oct; 43(10):1897-1903. PubMed ID: 27036386
[TBL] [Abstract][Full Text] [Related]
16. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
19. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
